D.J. St. Germain’s Takeda Pharmaceutical TAK Stock Holding History

D.J. St. Germain’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-15	Closed	-$236	–	776
2023 Q2	$236	Buy	+15	New	+$246	﹤0.01%	701

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.J. St. Germain's TAK Position: Q3 2023 in Review

D.J. St. Germain sold out of Takeda Pharmaceutical (TAK) in Q3 2023, closing a stake of 15 shares — an estimated $236 sold.

D.J. St. Germain first reported a position in TAK in Q2 2023 and held it in 1 quarter. The position peaked at $236 in Q2 2023. 312 funds tracked by Wall St. Rank hold TAK as of Q3 2023.

D.J. St. Germain reported no remaining Takeda Pharmaceutical position as of Q3 2023 after selling out during the quarter.
D.J. St. Germain sold 15 Takeda Pharmaceutical shares in Q3 2023, an estimated $236.
D.J. St. Germain first reported a position in Takeda Pharmaceutical in Q2 2023 and held it in 1 quarter.
D.J. St. Germain's Takeda Pharmaceutical position peaked at $236 in Q2 2023.
312 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2023.

Based on D.J. St. Germain's 13F filing for Q3 2023, filed 23 Oct 2023.